Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Document Verification Completed - Haaaa-leluiah!!
View:
Post by JocetooBad on Dec 09, 2021 11:42am

Document Verification Completed - Haaaa-leluiah!!

Finally! 

Calgary, Alberta--(Newsfile Corp. - December 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB :HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal investigators, the HS 12-01 database will be locked.

The database includes a total of 65 subjects who were randomized on a 2:1 basis to receive ACP-01 or a placebo, respectively. The Company is seeking the return of all of its intellectual property and assets from Aspire Health Sciences, LLC, including the randomization key(s) required to complete the statistical analyses of the trial.
Link: https://stockhouse.com/news/press-releases/2021/12/09/hemostemix-announces-soft-lock-of-database-as-source-document-verification

Comment by ENEMENEMYNEMO on Dec 09, 2021 5:26pm
Yeah but finally they admit to not having the randomization keys so this really means nothing... New lawsuit filed last week.  Hem plaintiffs claiming some serious charges against Aspire. I'm afraid that will hold up everything for another year!!!
Comment by spectator51 on Dec 09, 2021 6:22pm
This may never end. Mr Smeek has some explaining to do, we are being left in the dark, he failed to mention all these issues when raising money a year ago. Out right lies!.
Comment by TimBennethae on Dec 16, 2021 1:16pm
This post has been removed in accordance with Community Policy
Comment by ENEMENEMYNEMO on Dec 18, 2021 9:55am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities